Globe Life (NYSE:GL) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Globe Life (NYSE:GL) announced its earnings results on Wednesday. The company reported $3.61 EPS for the quarter, missing analysts’ consensus estimates of $3.67 by ($0.06), Zacks reports. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.59 billion. Globe Life had a return on equity of 20.94% and a net margin of 19.38%.Globe Life’s revenue for the quarter was up 8.0% compared to the same quarter last year. During the same quarter last year, the firm posted $3.05 EPS. Globe Life updated its FY 2026 guidance to 15.550-15.950 EPS.

Globe Life Stock Performance

GL stock opened at $183.71 on Thursday. Globe Life has a twelve month low of $122.48 and a twelve month high of $191.55. The firm has a market cap of $14.26 billion, a price-to-earnings ratio of 12.70 and a beta of 0.47. The business’s fifty day simple moving average is $168.37 and its two-hundred day simple moving average is $152.54. The company has a quick ratio of 0.07, a current ratio of 0.07 and a debt-to-equity ratio of 0.38.

Globe Life Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Monday, July 6th will be paid a $0.33 dividend. The ex-dividend date is Monday, July 6th. This represents a $1.32 dividend on an annualized basis and a yield of 0.7%. Globe Life’s dividend payout ratio (DPR) is presently 9.13%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on GL shares. Morgan Stanley raised their price target on Globe Life from $181.00 to $208.00 and gave the stock an “overweight” rating in a research report on Monday, July 6th. Wells Fargo & Company increased their target price on shares of Globe Life from $172.00 to $193.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Weiss Ratings lowered shares of Globe Life from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday. Truist Financial lifted their price target on shares of Globe Life from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Finally, Keefe, Bruyette & Woods upped their price target on shares of Globe Life from $180.00 to $192.00 and gave the company an “outperform” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Globe Life presently has a consensus rating of “Moderate Buy” and an average price target of $187.60.

Trending Headlines about Globe Life

Here are the key news stories impacting Globe Life this week:

• Positive Sentiment: JPMorgan Chase & Co. raised its price target on Globe Life (GL) from $181 to $201 and kept an overweight rating, signaling confidence in the stock’s upside.
• Positive Sentiment: TD Cowen also lifted its price target on Globe Life (GL), from $215 to $225, while reiterating a buy rating, reinforcing bullish analyst sentiment.
• Positive Sentiment: The company reported second-quarter revenue of $1.60 billion, topping estimates, and net operating income of $3.61 per share versus $3.27 a year ago, showing continued earnings growth despite the EPS miss.
• Neutral Sentiment: Globe Life (GL) issued FY 2026 EPS guidance of $15.55 to $15.95, which is close to Wall Street expectations but slightly below the midpoint of consensus.
• Negative Sentiment: Quarterly EPS of $3.61 missed the consensus estimate of $3.67, which may limit some of the upside from the earnings report.

Insider Activity

In related news, Director Cheryl Alston sold 8,258 shares of Globe Life stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $179.24, for a total transaction of $1,480,163.92. Following the completion of the sale, the director owned 16,621 shares in the company, valued at $2,979,148.04. This trade represents a 33.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO James Matthew Darden sold 4,663 shares of the business’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $153.88, for a total transaction of $717,542.44. Following the completion of the sale, the chief executive officer directly owned 58,451 shares of the company’s stock, valued at approximately $8,994,439.88. This trade represents a 7.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 124,187 shares of company stock valued at $19,529,414. Insiders own 2.11% of the company’s stock.

Institutional Trading of Globe Life

A number of large investors have recently modified their holdings of GL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Globe Life by 6.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,391 shares of the company’s stock valued at $1,237,000 after purchasing an additional 607 shares in the last quarter. NewEdge Advisors LLC grew its position in shares of Globe Life by 368.1% during the 1st quarter. NewEdge Advisors LLC now owns 6,806 shares of the company’s stock worth $897,000 after buying an additional 5,352 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Globe Life by 11.5% during the first quarter. Goldman Sachs Group Inc. now owns 563,021 shares of the company’s stock valued at $74,161,000 after buying an additional 58,163 shares during the period. Empowered Funds LLC purchased a new position in shares of Globe Life during the first quarter valued at $428,000. Finally, Focus Partners Wealth raised its holdings in shares of Globe Life by 8.3% in the first quarter. Focus Partners Wealth now owns 8,559 shares of the company’s stock valued at $1,127,000 after acquiring an additional 656 shares in the last quarter. Hedge funds and other institutional investors own 81.61% of the company’s stock.

Globe Life Company Profile

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.